Skip to main content
Healthcare

STAT+: In Duchenne muscular dystrophy, a promising therapy is available to a fortunate few

STAT+: In Duchenne muscular dystrophy, a promising therapy is available to a fortunate few

Feed excerpt — reported by STAT News

The FDA has to decide how and when to encourage development of exon-skipping drugs, which show promise in treating muscular dystrophy.

MAP records observable characteristics of the original article (publisher, author, date, references, framing cues). MAP does not verify the article’s claims or score it. Read the full original story at STAT News →

Original Source

This article was syndicated from STAT News. All rights remain with the original publisher.